Ascentage Pharma Group International (FRA:36X)

Germany · Delayed Price · Currency is EUR

5.05

+0.25 (5.21%)

At close: Feb 20, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Development and Sale of Novel Small-Scale Therapies	980.65M	221.98M	209.71M	27.91M	12.45M
Development and Sale of Novel Small-Scale Therapies Growth	341.77%	5.85%	651.38%	124.18%	-14.21%
Total	980.65M	221.98M	209.71M	27.91M	12.45M
Total Growth	341.77%	5.85%	651.38%	124.18%	-14.21%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Mainland China	302.24M	221.98M	209.71M	14.97M	1.71M
Mainland China Growth	36.15%	5.85%	1301.32%	774.63%	185.17%
Switzerland	678.42M	-	-	-	-
United States	-	-	4.00K	12.95M	10.74M
United States Growth	-	-	-99.97%	20.54%	-22.81%
Total	980.65M	221.98M	209.71M	27.91M	12.45M
Total Growth	341.77%	5.85%	651.38%	124.18%	-14.21%

Source: S&P Global Market Intelligence.